KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Current Liabilities for 18 consecutive years, with $1.3 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 25.46% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, up 25.46%, while the annual FY2025 figure was $1.5 billion, 23.61% up from the prior year.
  • Total Current Liabilities hit $1.3 billion in Q1 2026 for Alnylam Pharmaceuticals, down from $1.5 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.6 billion in Q3 2025 and bottomed at $606.0 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $1.0 billion, with a median of $967.8 million recorded in 2023.
  • Year-over-year, Total Current Liabilities grew 10.38% in 2022 and then soared 39.85% in 2024.
  • Alnylam Pharmaceuticals' Total Current Liabilities stood at $767.9 million in 2022, then grew by 26.03% to $967.8 million in 2023, then increased by 22.58% to $1.2 billion in 2024, then grew by 23.61% to $1.5 billion in 2025, then dropped by 7.97% to $1.3 billion in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $1.3 billion, $1.5 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.